Trials / Completed
CompletedNCT06507475
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
Real World Effectiveness of Oral Semaglutide in Thailand Patients With Type 2 Diabetes: an Observational, Multicentre, Retrospective Cohort Study REAL-world Effectiveness of Oral Semaglutide In a Cohort of Thai patientS With Type 2 Diabetes treatED With Oral Antidiabetic Medications (REALISED) Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 209 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. |
Timeline
- Start date
- 2024-09-07
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
- First posted
- 2024-07-18
- Last updated
- 2025-12-30
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT06507475. Inclusion in this directory is not an endorsement.